Dr Reddy's Expands Global Footprint With Strategic US Pharma Partnership

The company was informed by Dr Reddy’s Laboratories on Wednesday about the licensing agreement with the US-based company Ingenus Pharmaceuticals LLC, granting it exclusive rights in the US market to introduce the cancer treatment drug Cyclophosphamide injection in the US market. According to a regulatory filing by Dr Reddy's, Dr. Reddy’s Laboratories Inc., a fully-owned subsidiary, has signed an agreement with a Delaware limited liability company to commercialize Cyclophosphamide injection RTD (500mg/2.5ml, 1g/5ml, 2g/10ml).

As part of the deal, Dr Reddy’s will pay Ingenus only 50% of the calculated profit share of the sales of the drug in the US market. The company mentioned that “No other consideration (is) payable. The NDA covering the product will be assigned to Dr Reddy’s USA. The parties will enter into a commercial supply agreement pursuant to which Ingenus will supply the product to Dr Reddy’s USA.”